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Hyperbaric oxygen therapy (HBOT) has been investigated as 
a primary/adjunctive treatment for a number of injuries and 
medical conditions including traumatic ischemia, necrotizing 
soft tissue injuries, non-healing ulcers and osteoradionecrosis, 
but the results are controversial. There is insufficient evidence 
to support or reject the use of HBOT to quicken healing or 
to treat the established non-union of fractures. However, in 
patients with fibromyalgia, HBOT reduces brain activity in 
the posterior cortex and increases it in the frontal, cingulate, 
medial temporal and cerebellar cortices, thus leading to 
beneficial changes in brain areas that are known to function 
abnormally. Moreover, the amelioration of pain induced by 
HBOT significantly decreases the consumption of analgesic 
medications. In addition, HBOT has anti-inflammatory and 
oxygenatory effects in patients with primary or secondary 
vasculitis. This review analyzes the efficacy and limitations of 
HBOT in orthopedic and rheumatologic patients.
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T he Undersea and Hyperbaric Medicine Society (UHMS) defines hyperbaric oxygen therapy as, “an intervention 
in which an individual breathes near 100% oxygen intermit-
tently while inside a hyperbaric chamber that is pressurized to 
greater than sea level pressure (1 atmosphere absolute [ata])” 
[1]. Hyperbaric oxygen therapy (HBOT) increases hemoglobin 
saturation and leads to a tenfold to twentyfold increase in the 
amount of oxygen dissolved in blood plasma, which is more 
available to tissues than oxygenated hemoglobin, and makes 
it possible to deliver greatly increased partial oxygen pressure 
to tissues. It can be delivered in a high-pressure multi-place, 
high-pressure mono-place, or low-pressure mono-place cham-
bers. For clinical purposes, the pressure must be ≥ 1.4 ata, and 
typically involves pressurization to between 1.5 and 3.0 ata for 
periods of 60–120 minutes one or more times daily. The use of 
HBOT can be traced to the 1600s. The first well-known cham-
ber was built and run by a British clergyman named Henshaw 
in 1662, but it was not until 1917 that German inventors 
Bernhard and Heinrich Dräger successfully applied pressurized 
oxygen to treat decompression illness due to diving accidents. 
Decompression sickness remained the only indication for a 
long time, but HBOT has more recently been investigated as a 
primary or adjunctive treatment for a number of injuries and 
medical conditions, including traumatic ischemia, necrotizing 
soft tissue injuries, non-healing ulcers, and osteoradionecrosis. 
The UHMS and European Consensus Conference have periodi-
cally updated the indications [2]. The last revision included 14 
indications [Table 1]. 
The aim of this article is to analyze the evidence of the effi-
cacy of HBOT in orthopedics and rheumatological diseases.
mEThoDs
We searched the MEDLINE database (PubMed, National 
Library of Medicine, Bethesda, MD, USA) and used combina-
tions of the key words “hyperbaric oxygen therapy,” “ulcers,” 
“vasculitis,” “fractures,” “rheumatologic(al) diseases,” “pain,” 
and “fibromyalgia.” The reference lists of all of the selected 
articles were also scanned for references not identified in the 
initial search. We limited our search to citations from January 
1990 to December 2016. 
hBoT AnD FRACTuREs 
The treatment of fractures is intended to re-establish the struc-
tural integrity of a fractured bone and restore function to the 
injured body part; however, the process of fracture healing is 
sometimes impaired and leads to delayed union or, in some cases, 
hypervascular (hypertrophic) or avascular (atrophic) non-union 
(i.e., no healing 6 months after the injury), which often require 
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further in-patient care and, in many cases, multiple surgeries 
and prolonged rehabilitation. Animal studies have shown that 
HBOT increases bone generation and the removal of dead bone 
but, although there have been reports of clinical improvements 
in patients with established non-union fractures, the evidence 
supporting its effectiveness in treating non-healing fractures is 
still weak [3,4]. HBOT has been used to treat crush injuries and 
compartment syndromes in a limited number of centers around 
the world, and is often recommended in the hyperbaric medicine 
literature [5,6]. A wide range of animal models of soft tissue flap 
ischemia have demonstrated 
the ability of HBOT to pre-
serve acutely ischemic tissue 
and improve flap survival, and 
others have demonstrated sub-
stantially accelerated and qualitatively better healing of muscles, 
tendons, peripheral nerves and bone [7-11].
HBOT can significantly reduce post-trauma edema and 
moderate inflammatory processes, as well as up-regulate various 
endogenous antioxidant systems [12]. During or immediately 
after ischemia, it can inhibit ischemia-reperfusion injuries via 
mechanisms that include the inhibition of β2 integrin-mediated 
neutrophil adhesion during reflow [12]. It also accelerates 
angiogenesis and fibroblast function to increase the healing of 
problematic wounds [13]. Two randomized, controlled trials 
have shown that HBOT improves arterial flow and local skin 
perfusion, increases the rate of complete healing, and reduces 
the need for further surgery compared to standard treatment, 
but they did not report any functional measures or long-term 
outcomes [14,15]. 
The still ongoing Hyperbaric Oxygen for Lower Limb 
Trauma (HOLLT) study is an international, multi-center, open-
label, randomized trial involving patients with crush injuries 
that caused complex fractures in the lower leg [16]. Patients 
with an acute, open fracture of the tibia and severe soft tissue 
injury (Gustilo grade 3) were randomized to a standard surgical 
protocol with or without HBOT in the acute phase (within 48 
hours of injury). HBOT was administered in 90 minute sessions 
at 2.4 ata twice daily for the first 3 days, and then once daily 
until reaching a total of at least 12 sessions. The primary aim of 
the study was to evaluate the incidence of acute fracture wound 
complications, defined as the occurrence of significant soft tis-
sue necrosis developing after initial surgery and/or significant 
wound infection within 2 weeks of the injury. The early second-
ary outcomes (14 days after injury) that were measured included 
the date, time and nature of all operative procedures; the length 
of stay in the intensive care unit; and the length of acute hos-
pitalization. The late secondary outcomes (3–24 months after 
injury) that were assessed included the occurrence of soft tis-
sue infection, osteomyelitis, any other wound complications, 
whether the patient was able to bear his or her weight on the 
injured leg, and the number and nature of any other surgical 
procedures required [16]. The results have yet to be published. 
There is currently insufficient evidence to support or reject the 
use of HBOT as a means of accelerating the healing of acute 
injuries or treating established non-union fractures. However, 
all of the results and actions of HBOT are attractive in setting of 
orthopedic, soft tissue traumas, and, we believe, in facial trau-
mas involving the mandible. The mandible is frequently injured 
after facial trauma, and the condyle is involved in about 25–40% 
of mandibular fractures [17]. The management of mandibular 
condylar fractures (MCFs) is still controversial [18]. A recent 
meta-analysis showed that, 
compared to closed treat-
ment, open reduction and 
rigid internal fixation (ORIF) 
leads to better functional and 
clinical outcomes, including a maximal inter-incisal opening, 
latero-protrusive movement, protrusive movement, malocclu-
sion, and reduction of pain and chin deviation on mouth open-
ing [19]. However, it is contraindicated for the management of 
bilateral intracapsular condylar head fractures because of the 
high risk of avascular necrosis and the associated loss of func-
tioning condyle, the possible development of fibrous or osseous 
ankylosis, and the subsequent need to remove loose hardware 
[20]. Active mandibular movement is particularly important 
in preventing ankylosing, avascular necrosis and the loss of 
functioning condyles in this highly vascularized and osteogenic 
environment [18]. Given these data we treated a patient with 
a diagnosis of bilateral compound multi-fragmented intra-
capsular fractures of the mandibular condylar heads by means of 
computed tomography (CT) with a total of 80 HBOT sessions, 
combined with physiotherapy and opening exercises for about 
12 months (2–3 sessions/week with an exceptional improve-
ment in the signs and symptoms of MCF confirmed by mag-
netic resonance imaging (MRI) [unpublished data]. We suggest 
hyperbaric oxygen therapy (hBoT) has 
been investigated as a primary/adjunctive 
treatment for a number of injuries and medical 
conditions, but the results are controversial
Table 1. Undersea and Hyperbaric Medicine Society’s indications for 
HBOT [2]
• Arterial air or gas embolism 
• Acute decompression illness
• Acute carbon monoxide poisoning/carbon monoxide poisoning complicated 
by cyanide poisoning
• Necrotising soft tissue infections
• Acute thermal burns
• Crush injury, compartment syndrome, other traumatic ischemias
• Gas gangrene (clostridial myonecrosis)
• Compromised graft or flap preservation
• Arterial insufficiency: central renal artery occlusion, to enhance healing of 
selected problem wounds
• Intracranial abscesses
• Severe anemia
• Chronic refractory osteomyelitis
• Osteoradionecrosis, soft tissue radiation necrosis 
• Sudden idiopathic sensorineural hearing loss
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NMDA receptors, and decreased expression of spinal neuronal 
NOS (nNOS) and inducible NOS (iNOS) [27]. 
The clinical usefulness of HBOT in treating different types of 
human pain has been investigated in conditions such as chronic 
headache, complex regional pain syndrome, trigeminal neural-
gia, and fibromyalgia. Five randomized, controlled trials have 
shown that HBOT has some efficacy in treating acute migraine 
attacks but not in preventing future attacks [28], and various 
authors have found that it can be effective in treating and pre-
venting cluster headache [29]. However, as the methodological 
quality of all of these studies was moderate to low, and they 
were underpowered because of the small number of patients, 
further studies of larger patient series with more robust design 
are required. 
HBOT has led to promising results in complex regional pain 
syndrome, and the findings of one small trial suggest that it may 
also be useful in treating idiopathic trigeminal neuralgia [28].
FiBRomyAlGiA AnD ChRoniC FATiGuE
Fibromyalgia syndrome is one of the most common causes of 
chronic widespread pain. It is characterized by reduced pain 
thresholds (hyperalgesia) and pain with normally innocuous 
stimuli (allodynia) [30]. Fibromyalgia is common, with a preva-
lence of 2% in the general population. However, its diagnosis 
and management remain a challenge for patients and healthcare 
professionals. The diagnosis of fibromyalgia often takes more 
than 2 years with an average of 3.7 consultations with differ-
ent physicians [30]. Although pain is the dominant symptom 
in fibromyalgia, other symptoms such as fatigue, non-refreshed 
sleep, mood disturbance and 
cognitive impairment are com-
mon. Patients with fibromyalgia 
have a diverse combination and 
varying severity of these symp-
toms. Co-morbidities, especially depression and anxiety, are 
also common but not universal in all patients. Therefore, fibro-
myalgia is a heterogeneous and complex condition. The quality 
of life in almost all of the patients with fibromyalgia syndrome 
is reduced. Both impaired physical functions and emotional 
impact adversely affect the quality of life of fibromyalgia patients. 
Approximately 50% of all the patients have difficulty with routine 
daily activities while 30–40% have to stop work or change their 
employment. The societal cost of fibromyalgia due to reduced 
productivity is high. As fibromyalgia is a complex syndrome 
associated with a wide range of symptoms, treatment should be 
tailored to the individual, addressing their particular needs and 
targeting their most distressing symptoms. The best strategy is to 
use a multidisciplinary approach to treatment, using both phar-
macological and non-pharmacological interventions as required 
[31]. Non-pharmacological treatments that have been tested in 
fibromyalgia syndrome include: exercise, cognitive behavioral 
therapy, homeopathy, physiotherapy, acupuncture, magnetism, 
that HBOT, combined with early and aggressive physiotherapy, 
had a beneficial effect on bilateral MCF, particularly because it 
acted on capsular elasticity, although it did not lead to the disap-
pearance of bone dislocations revealed by MRI. Furthermore, 
HBOT combined with early and aggressive physiotherapy can 
have a beneficial effect on fractures by reducing the complica-
tions of the orthopedic injuries and preventing the fibroses 
adhesions induced by the aggressive physiotherapy [13]. It can 
also improve clinical outcomes such as acute and chronic pain 
because of the immediate and prolonged release of nitric oxide 
and endogenous nitric oxide opioids counteracting abnormal 
brain pain processing [21,22]. 
In conclusion our current understanding of HBOT is that 
it can reduce the complications of orthopedic injuries and 
thus improve outcomes [13]. It is hoped that the results of the 
HOLLT study, case reports and future trials will provide new 
data about the usefulness of HBOT in these types of injuries.
hBoT AnD pAin 
ChRoniC pAin AnD DysFunCTionAl synDRomEs
The management of chronic pain is sometimes challenging and 
requires a multidisciplinary approach. Most pharmacological 
and physical therapies only slightly or temporarily ameliorate 
pain symptoms, and often they have adverse effects that interfere 
with the patient’s quality of life and lead to non-adherence [23]. 
The analgesic effects of HBOT have been studied in nociceptive, 
inflammatory and neuropathic pain models, and may be useful 
for the treatment of various chronic pain syndromes [21,22]. 
HBOT has shown that it 
inhibits nociception in murine 
models of pain, an effect that is 
probably mediated by the neural 
nitric oxide-dependent release of 
opioid peptides [21]. This effect acts centrally but also involves 
the release of neuronal dynorphins and the activation of µ- and 
k-opioid receptors in the spinal cord [22]. HBOT may also play 
a role in inhibiting the inflammatory response following injury 
and the associated inflammatory pain, as it has been shown 
to be as effective as aspirin in decreasing inflammation and 
mechanical hypersensitivity in a rat model of arthritis [24]. 
Promising results have been obtained in animal models 
of neuropathic pain treated with HBOT. Gu and colleagues 
[25] found that daily treatment at 3.0 ata for 7 days starting 30 
minutes after chronic constriction-induced sciatic nerve injury 
reduced the severity and duration of thermal hyperalgesia and 
mechanical allodynia in rats, both of which are behavioral 
indicators of neuropathic pain. This effect has been associated 
with decreased production of pro-inflammatory cytokines 
such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β 
[26], changes in the phosphorylation of proteins thought to 
be involved in the development of neuropathic pain such as 
In patients with fibromyalgia, hyperbaric 
oxygen therapy (hBoT) led to beneficial 
changes in brain areas that are known to 
function abnormally and to ameliorate pain
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in patients with RA. In the majority of cases, the etiology was 
vasculitis, but other causes included venous disease, peripheral 
artery disease, and granulomatous dermatitis. In a retrospec-
tive review by Chia and Tang [37] regarding the outcomes of 
chronic leg ulcers in patients with rheumatologic diseases (RA, 
SLE, overlap syndromes, systemic sclerosis and ankylosing 
spondylitis), 15 of the 29 patients with leg ulcers had a diagnosis 
of RA, 8 had a diagnosis of SLE, 3 were diagnosed with overlap 
syndromes, 1 with systemic sclerosis, and 1 with ankylosing 
spondylitis. In the majority of cases, the patients required an 
addition or change in immunosuppressive agents and/or com-
pression therapy, but four patients underwent HBOT due to no 
beneficial response to other treatment options. Furthermore, 
HBOT has recently been used to treat ulcers in systemic scle-
rosis patients failing to respond to conventional therapies with 
promising results.
Systemic vasculitides are a frequent cause of non-healing skin 
ulcers, which have a significant impact on co-morbidity, mortal-
ity and therapeutic costs. By altering local hypoxic conditions, 
HBOT can facilitate wound-healing and energy-consumption 
processes. Moreover, hyperoxia has an anti-inflammatory effect 
on the vascular bed. HBOT has long been used in addition to 
antibiotics, debridement and revascularisation in the treatment 
of chronic non-healing wounds associated with diabetes or 
non-diabetic vascular insufficiency, but its use in conditions, 
such as vasculitides, is still under debate [2]. In 2006, Efrati and 
co-authors [38] published an inter-
esting study on the use of HBOT in 
35 patients with vasculitis-induced 
severe ulcers, which did not heal 
despite intense immunosuppressive 
treatment. The baseline treatment protocol consisted of the 
administration of 100% O2 at a pressure of 2 ata for 90 minutes 
five times a week for 4 weeks. Additional sessions were planned 
in selected cases. After HBOT, 28 patients (80%) showed 
complete healing and four showed partial healing; only three 
patients did not respond, and none of the patients experienced 
any HBOT-related side effects. Ulcer tissue oxygenation was 
evaluated by measuring transcutaneous oxygen pressure (TcPO2) 
using a pulse oximeter before and after HBOT. There was a sig-
nificant increase in TcPO2 after HBOT, which explains the high 
response rate. Interestingly, no significant differences in baseline 
characteristics or tissue oxygenation were observed between the 
non-responders and the patients whose wounds completely 
healed. It is therefore difficult to predict who will benefit from 
HBOT, and further studies are needed for clarification.
Hyperbaric oxygenation at 2–2.5 ata fully oxygenates hemo-
globin, and the amount of dissolved oxygen in plasma increases 
more than tenfold, thus exceeding tissue oxygen requirements. 
HBOT therefore generates a positive gradient for oxygen diffu-
sion from functioning capillaries to ischemic tissue sites and, by 
altering conditions of local hypoxia, facilitates wound-healing 
dietary alterations and laser therapy [31]. These interventions 
are generally safe and therefore long-term use is not detrimental. 
Excessive pain in fibromyalgia may be due to hyper-excitability 
of the pain processing pathways and under-activity of the pain 
inhibiting pathways in the brain. Comparisons of single-photon 
emission computed tomography (SPECT) findings in fibromyal-
gia patients and healthy subjects revealed high levels of activity in 
the somatosensory cortex and reduced activity in the frontal, cin-
gulate, medial temporal and cerebellar cortices [32]. It has been 
shown that HBOT increases cell metabolism, reduces apoptosis, 
alleviates oxidative stress, and increases neurotrophin and nitric 
oxide levels by enhancing mitochondrial function in neurons and 
glial cells, and it may even promote the neurogenesis of endog-
enous neural stem cells [33]. HBOT-induced neuroplasticity also 
leads to the repair of chronically impaired brain functions in 
patients who have experienced a stroke or mild traumatic brain 
injury with prolonged post-concussion syndrome. Furthermore, 
there is a body of evidence supporting the use of HBOT to 
decrease inflammation and pain behaviors in rodents, but there 
is a lack of evidence concerning its clinical usefulness in human 
pain conditions. However, Yildiz et al. [34] found that HBOT 
significant reduced the number and threshold of tender points, 
and an Israeli group [35] evaluated its efficacy in improving the 
symptoms of fibromyalgia patients by rectifying their typically 
altered brain functions. The study endpoints included a tender 
point count, pain threshold measurements, functional impair-
ment, and brain activity as assessed 
by means of SPECT. HBOT led to a 
statistically significant improvement 
in the mean dolorimeter threshold 
and the number of tender points; 
furthermore, it reduced brain activity in the posterior cortex 
and increased activity in the frontal, cingulate, medial temporal 
and cerebellar cortices, thus leading to beneficial changes in the 
activity of specific brain areas whose functions are known to be 
abnormal in fibromyalgia patients. Furthermore, the post-HBOT 
amelioration of pain levels led to a significant decrease in the 
consumption of analgesic medications [36]. 
The efficacy of HBOT has recently been studied in patients 
with chronic fatigue syndrome (CFS), a chronic disease with 
social effects due to the subject’s inability to fulfill their work, 
social and family responsibilities. In a small study of 16 patients, 
Akarsu and colleagues [36] found that HBOT decreased the 
severity of symptoms and increased the patient’s quality of life. 
However, further studies are needed to confirm this efficacy in 
fibromyalgia and CFS patients.
hBoT in sEConDARy AnD pRimARy vAsCuliTis 
The prevalence of chronic leg ulcers in patients with an underly-
ing rheumatologic disease is reported to range from 5.6% in 
patients with systemic lupus erythematosus (SLE) to about 9% 
hyperbaric oxygen therapy 
(hBoT) has anti-inflammatory and 
oxygenatory effects in patients with 
primary or secondary vasculitis 
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processes such as fibroblast proliferation or angiogenesis. 
Furthermore, it has a beneficial effect on non-ischemic ulcers, 
possibly because of its anti-inflammatory action. A number 
of animal models have shown that HBOT inhibits vascular 
inflammatory responses by reducing the rolling and adhesion of 
neutrophils in the micro-circulation of the brain, liver, skeletal 
muscles and bowel [12,13]. It has also been shown to enhance 
plasma anti-oxidant defenses, and may contribute to angiogen-
esis and regulate vascular tone by stimulating vascular endo-
thelial growth factor and interleukin 6 release and decreasing 
endothelin-1, thus ultimately fostering wound healing [12,13]. 
Its efficacy has been investigated in various conditions, but 
the evidence for most is scant even though a recent Cochrane 
review has reported the short-term benefits of HBOT in the 
healing of diabetic foot ulcers. Therefore, no definite conclusions 
can be drawn concerning its effects on chronic wound healing 
with other underlying etiologies [39].
osTEonECRosis 
Few studies of HBOT as joint-preserving treatment for symp-
tomatic early-stage osteonecrosis of the femoral head have been 
published. However a study reviewed the files of 68 patients who 
were treated with HBOT. The study comprised 78 symptomatic 
joints diagnosed with Steinberg stage I and II osteonecrosis by 
means of MRI [40]. At the time of follow-up, 93% of the joints 
survived. Mean Modified Harris Hip Score and Short Form-12 
health survey (SF-12) improved from 21 to 81 (P < 0.0001). The 
mean physical component of the SF-12 questionnaires showed 
improvement from 24 to 46 (P < 0.0001), and the mean mental 
component of the SF-12 improved from 54 to 59 (P < .0001) [40].
The cellular and molecular mechanism through which 
HBOT improves osteonecrosis remains unclear. However, the 
data from a basic study showed that HBOT has a direct suppres-
sive effect on osteoclast differentiation and activity in normoxic 
and hypoxic conditions. This result would appear to be associ-
ated with a reduced response to the receptor activator of nuclear 
factor kappa-B ligand (RANKL) and secondary to changes in 
HIF, RANK, and NFATc1 gene expression. This result suggests 
that the beneficial effects of adjunctive HBOT on necrotic bone 
may occur in part due to a reduction in aberrant osteoclast 
activity [3]. 
These data suggest that HBOT is effective in osteonecrosis, 
although further studies are needed to confirm these clinical 
and basic findings.
limiTATions on ThE usE oF hBoT in CliniCAl pRACTiCE
One limitation of HBOT is the risk of adverse effects, including 
pressure-induced damage to the ears, sinuses and lungs last-
ing from 1 day to 2 weeks, temporary worsening of myopia 
for several weeks, and claustrophobia during therapy. Oxygen 
poisoning may manifest itself acutely as a neurological event 
(often acute), but only a problem during therapy), or it may 
accumulate slowly and decrease respiratory function. It is also 
necessary to take into account the high costs of the technique. 
ConClusions
Future research should concentrate on identifying which 
patients can benefit from HBOT, defining the optimal time for 
the intervention, and drawing up specific dose-response curves 
for each condition. However, this type of evaluation may be 
complicated for at least two reasons. First, the optimal dose and 
duration of HBOT is not well established, even for recognized 
indications. Second, patient blinding may be a problem as there 
cannot be any true placebo condition, although it may be pos-
sible to use a short exposure vs. high pressure at the beginning 
of a session to replicate the sensation of HBOT. However, this 
modification may lead to short periods of increased plasma 
oxygen partial pressure (i.e., short period of increased plasma 
oxygen) affecting the results. Nevertheless, there is a real need 
for more adequately powered trials designed to minimize all 
kinds of bias and to establish the appropriate indications for 
HBOT, both in orthopedic and rheumatologic conditions. 
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Bioresorbable vascular scaffolds were developed to overcome 
the shortcomings of drug-eluting stents in percutaneous 
coronary intervention (PCI). Wykrzykowska et al. performed 
an investigator-initiated, randomized trial to compare an 
everolimus-eluting bioresorbable scaffold with an everolimus-
eluting metallic stent in the context of routine clinical 
practice. The authors randomly assigned 1845 patients 
undergoing PCI to receive either a bioresorbable vascular 
scaffold (924 patients) or a metallic stent (921 patients). The 
primary endpoint was target-vessel failure (a composite of 
cardiac death, target-vessel myocardial infarction, or target-
vessel revascularization). The median follow-up was 707 
days. Target-vessel failure occurred in 105 patients in the 
scaffold group and in 94 patients in the stent group (2 year 
cumulative event rates 11.7% and 10.7%, respectively, hazard 
ratio [HR], 1.12, 95% confidence interval [CI], 0.85–1.48, 
P = 0.43); event rates were based on Kaplan–Meier estimates 
in time-to-event analyses. Cardiac death occurred in 18 
patients in the scaffold group and in 23 patients in the 
stent group (2-year cumulative event rates 2.0% and 2.7%, 
respectively), target-vessel myocardial infarction occurred in 
48 patients in the scaffold group and in 30 patients in the 
stent group (2 year cumulative event rates 5.5% and 3.2%, 
respectively), and target-vessel revascularization occurred in 
76 patients in the scaffold group and in 65 patients in the 
stent group (2 year cumulative event rates 8.7% and 7.5%, 
respectively). Definite or probable device thrombosis occurred 
in 31 patients in the scaffold group as compared with 8 
patients in the stent group (2 year cumulative event rates, 
3.5% vs. 0.9%, HR 3.87, 95%CI 1.78–8.42, P < 0.001).
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